Matches in Nanopublications for { ?s ?p "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1248418.RAWtSAosHEWRZNsNpfdlC0DRNvk6WofRGysGGLH3pr-Cg130_assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248418.RAWtSAosHEWRZNsNpfdlC0DRNvk6WofRGysGGLH3pr-Cg130_provenance.
- NP1248419.RAZXksHpKnSMQE1Wpg-eolZiRZsNziTDazekLw8rcKkkM130_assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248419.RAZXksHpKnSMQE1Wpg-eolZiRZsNziTDazekLw8rcKkkM130_provenance.
- NP1248421.RAEL7iDFD-qT53IaqchuUKwyh-CCrH6JCsJl2gOBei2ag130_assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248421.RAEL7iDFD-qT53IaqchuUKwyh-CCrH6JCsJl2gOBei2ag130_provenance.
- NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_assertion description "[Our results support clinical trial data showing that PsA skin and joint disease are similarly responsive to TNF antagonists, while IL-17 antagonists have better results in PsA skin than in PsA joints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248420.RAy2FbTr2eYct2wLdk0cIwriOj9VdTl28CzPDvpls8CCA130_provenance.